SEATTLE — Patients with ALS who were treated with CNM-Au8 — a gold nanocrystal suspension — showed improvements in survival, a speaker said at the 2022 American Academy of Neurology annual meeting. “This is a phase 2 study and needs a larger phase 3 confirmatory, international clinical trial,” Matthew Kiernan, PhD, DSc, the Bushell Chair of […]

NeuroSense Therapeutics has enrolled and dosed the first healthy subject in the pharmacokinetic (PK) study of its combination drug candidate, PrimeC, to treat amyotrophic lateral sclerosis (ALS). PrimeC comprises a fixed-dose mixture of ciprofloxacin and celecoxib, which are approved by the US Food and Drug Administration (FDA).

The week began with new partnerships formed in the life sciences industry as several firms entered into licensing deals and collaboration commitments. Here’s a look at the latest in life science licensing and collaboration deals. Telix Pharmaceuticals and Eli Lilly Telix Pharmaceuticals signed a license agreement with Eli Lilly and Company, granting Telix exclusive global rights to develop […]